BIOMAT Database Logo BIOMAT Database Logo

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. 2015

A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
South Texas Accelerated Research Therapeutics LLC, San Antonio. Electronic address: atolcher@start.stoh.com.

BACKGROUND This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK inhibitor trametinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus. Secondary objectives included pharmacokinetic (PK) characterization and evaluation of clinical activity. METHODS A total of 67 patients with advanced solid tumors were enrolled in this open-label, single-arm, dose-escalation study. Dose escalation followed a 3 + 3 design. Patients were assigned to one of 10 different cohorts, involving either daily dosing with both agents or daily dosing with trametinib and intermittent everolimus dosing. This included an expansion cohort comprising patients with pancreatic tumors. PKs samples were collected predose, as well as 1, 2, 4, and 6 h post-dose on day 15 of the first treatment cycle. RESULTS Concurrent treatment with trametinib and everolimus resulted in frequent treatment-related adverse events, including mucosal inflammation (40%), stomatitis (25%), fatigue (54%), and diarrhea (42%). PK assessment did not suggest drug-drug interactions between these two agents. Of the 67 enrolled patients, 5 (7%) achieved partial response (PR) to treatment and 21 (31%) displayed stable disease (SD). Among the 21 patients with pancreatic cancer, PR was observed in 1 patient (5%) and SD in 6 patients (29%). CONCLUSIONS This study was unable to identify a recommended phase II dose and schedule of trametinib in combination with everolimus that provided an acceptable tolerability and adequate drug exposure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068338 Everolimus A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT. Zortress,40-O-(2-hydroxyethyl)-rapamycin,Afinitor,Certican,RAD 001,RAD001,SDZ RAD,SDZ-RAD,001, RAD,RAD, SDZ
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
February 2015, Clinical cancer research : an official journal of the American Association for Cancer Research,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
October 2015, Investigational new drugs,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
December 2016, Investigational new drugs,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
August 2012, The Lancet. Oncology,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
September 2019, Clinical cancer research : an official journal of the American Association for Cancer Research,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
October 2020, The oncologist,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
April 2020, Investigational new drugs,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
August 2013, Investigational new drugs,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
April 2020, Cancer chemotherapy and pharmacology,
A W Tolcher, and J C Bendell, and K P Papadopoulos, and H A Burris, and A Patnaik, and S F Jones, and D Rasco, and D S Cox, and M Durante, and K M Bellew, and J Park, and N T Le, and J R Infante
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
January 2015, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!